Table of Content

1. Key Insights

2. Executive Summary of Metabolic Acidosis

3. SWOT Analysis of Metabolic Acidosis

4. Metabolic Acidosis: Market Overview at a Glance

5. Metabolic acidosis: Disease Background and Overview
5.1. Introduction
5.2. Signs and Symptoms
5.3. Pathogenesis
5.4. Etiology
5.5. Effects of metabolic acidosis on the kidney

6. Diagnosis
6.1. Management of metabolic acidosis in CKD

7. Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM+3EM
7.3. Epidemiology Scenario: 7MM+3EM
7.3.1. Total Prevalence of CKD patients in the 7MM+3EM
7.3.2. Total Prevalence of Metabolic Acidosis in CKD patients of the 7MM+3EM
7.3.3. Total Prevalence of dRTA in the 7MM+3EM
7.3.4. Total Diagnosed Population of Metabolic Acidosis in the 7MM+3EM
7.3.5. Total Diagnosed Population of dRTA in the 7MM+3EM
7.3.6. Gender-Specific diagnosed cases of Metabolic Acidosis in the 7MM+3EM
7.3.7. Total Treated Population of Metabolic Acidosis in the 7MM+3EM
7.3.8. Total Treated Population of dRTA in the 7MM+3EM

8. The United States Epidemiology
8.1. Total Prevalent Population of Metabolic Acidosis in the United States
8.2. Total Prevalent Population of dRTA in the United States
8.3. Total Diagnosed Population of Metabolic Acidosis in the United States
8.4. Total Diagnosed Population of dRTA in the United States
8.5. Total Treated Population of Metabolic Acidosis in the United States
8.6. Total Treated Population of dRTA in the United States

9. EU-5 Epidemiology
9.1. Germany
9.1.1. Total Prevalent Population of Metabolic Acidosis in Germany
9.1.2. Total Prevalent Population of dRTA in Germany
9.1.3. Total Diagnosed Population of Metabolic Acidosis in Germany
9.1.4. Total Diagnosed Population of dRTA in Germany
9.1.5. Total Treated Population of Metabolic Acidosis in Germany
9.1.6. Total Treated Population of dRTA in Germany
9.2. France
9.2.1. Total Prevalent Population of Metabolic Acidosis in France
9.2.2. Total Prevalent Population of dRTA in France
9.2.3. Total Diagnosed Population of Metabolic Acidosis in France
9.2.4. Total Diagnosed Population of dRTA in France
9.2.5. Total Treated Population of Metabolic Acidosis in France
9.2.6. Total Treated Population of dRTA in France
9.3. Italy
9.3.1. Total Prevalent Population of Metabolic Acidosis in Italy
9.3.2. Total Prevalent Population of dRTA in Italy
9.3.3. Total Diagnosed Population of Metabolic Acidosis in Italy
9.3.4. Total Diagnosed Population of dRTA in Italy
9.3.5. Total Treated Population of Metabolic Acidosis in Italy
9.3.6. Total Treated Population of dRTA in Italy
9.4. Spain
9.4.1. Total Prevalent Population of Metabolic Acidosis in Spain
9.4.2. Total Prevalent Population of dRTA in Spain
9.4.3. Total Diagnosed Population of Metabolic Acidosis in Spain
9.4.4. Total Diagnosed Population of dRTA in Spain
9.4.5. Total Treated Population of Metabolic Acidosis in Spain
9.4.6. Total Treated Population of dRTA in Spain
9.5. The United Kingdom
9.5.1. Total Prevalent Population of Metabolic Acidosis in the United Kingdom
9.5.2. Total Prevalent Population of dRTA in the United Kingdom
9.5.3. Total Diagnosed Population of Metabolic Acidosis in the United Kingdom
9.5.4. Total Diagnosed Population of dRTA in the United Kingdom
9.5.5. Total Treated Population of Metabolic Acidosis in the United Kingdom
9.5.6. Total Treated Population of dRTA in the United Kingdom

10. Japan Epidemiology
10.1.1. Total Prevalent Population of Metabolic Acidosis in Japan
10.1.2. Total Prevalent Population of dRTA in Japan
10.1.3. Total Diagnosed Population of Metabolic Acidosis in Japan
10.1.4. Total Diagnosed Population of dRTA in Japan
10.1.5. Total Treated Population of Metabolic Acidosis in Japan
10.1.6. Total Treated Population of dRTA in Japan

11. Brazil Epidemiology
11.1.1. Total Prevalent Population of Metabolic Acidosis in Brazil
11.1.2. Total Prevalent Population of dRTA in Brazil
11.1.3. Total Diagnosed Population of Metabolic Acidosis in Brazil
11.1.4. Total Diagnosed Population of dRTA in Brazil
11.1.5. Total Treated Population of Metabolic Acidosis in Brazil
11.1.6. Total Treated Population of dRTA in Brazil

12. China Epidemiology
12.1.1. Total Prevalent Population of Metabolic Acidosis in China
12.1.2. Total Prevalent Population of dRTA in China
12.1.3. Total Diagnosed Population of Metabolic Acidosis in China
12.1.4. Total Diagnosed Population of dRTA in China
12.1.5. Total Treated Population of Metabolic Acidosis in China
12.1.6. Total Treated Population of dRTA in China

13. Mexico Epidemiology
13.1.1. Total Prevalent Population of Metabolic Acidosis in Mexico
13.1.2. Total Prevalent Population of dRTA in Mexico
13.1.3. Total Diagnosed Population of Metabolic Acidosis in Mexico
13.1.4. Total Diagnosed Population of dRTA in Mexico
13.1.5. Total Treated Population of Metabolic Acidosis in Mexico
13.1.6. Total Treated Population of dRTA in Mexico

14. Treatment of metabolic acidosis in CKD
14.1. Recommendations according to the GRADE methodology
14.2. Adverse effects of metabolic acidosis

15. Unmet Needs

16. Patient Journey of Metabolic Acidosis

17. Attribute Analysis of Metabolic Acidosis

18. Emerging Therapies
18.1. Veverimer (TRC101): Tricida
18.1.1. Product Description
18.1.2. Other Developmental Activities
18.1.3. Clinical Development
18.1.4. Product Profile
18.2. ADV7103: Advicenne Pharma
18.2.1. Product Description
18.2.2. Other Developmental Activities
18.2.3. Clinical Development
18.2.4. Product Profile

19. Metabolic Acidosis: 7MM+3EM Market Analysis
19.1. Key Findings
19.2. Market Size of Metabolic Acidosis in the 7MM+3EM
19.3. Market Size of Metabolic Acidosis by therapies in the 7MM+3EM

20. 7MM+3EM: Market Outlook
21. The United States: Market Size
21.1. Total Market size of Metabolic Acidosis in the United States
21.2. Market Size of Metabolic Acidosis by therapies in the United States
22. EU-5 countries: Market Size
22.1. Germany Market Size
22.1.1. Total Market size of Metabolic Acidosis in Germany
22.1.2. Market Size of Metabolic Acidosis by therapies in Germany
22.2. France Market Size
22.2.1. Total Market size of Metabolic Acidosis in France
22.2.2. Market Size of Metabolic Acidosis by therapies in France
22.3. Italy Market Size
22.3.1. Total Market size of Metabolic Acidosis in Italy
22.3.2. Market Size of Metabolic Acidosis by therapies in Italy
22.4. Spain Market Size
22.4.1. Total Market size of Metabolic Acidosis in Spain
22.4.2. Market Size of Metabolic Acidosis by therapies in Spain
22.5. The United Kingdom Market Size
22.5.1. Total Market size of Metabolic Acidosis in the United Kingdom
22.5.2. Market Size of Metabolic Acidosis by therapies in the United Kingdom
23. Japan: Market Size
23.1. Total Market size of Metabolic Acidosis in Japan
23.2. Market Size of Metabolic Acidosis by therapies in Japan
24. Brazil: Market Size
24.1. Total Market size of Metabolic Acidosis in Brazil
24.2. Market Size of Metabolic Acidosis by therapies in Brazil
25. China: Market Size
25.1. Total Market size of Metabolic Acidosis in China
25.2. Market Size of Metabolic Acidosis by therapies in China
26. Mexico: Market Size
26.1. Total Market size of Metabolic Acidosis in Mexico
26.2. Market Size of Metabolic Acidosis by therapies in Mexico
27. Access and Reimbursement Overview of Metabolic acidosis
28. KOL Views
29. Market Drivers
30. Market Barriers
31. Appendix
31.1. Bibliography
31.2. Report Methodology
32. DelveInsight Capabilities
33. Disclaimer
34. About DelveInsight



List of Figures


Figure 1: Mechanisms of acid-mediated tubule interstitial fibrosis in chronic kidney disease (CKD)
Figure 2: Algorithm recommended by the experts for etiological diagnosis of metabolic acidemia metabolic acidosis
Figure 3: Management of chronic metabolic acidosis (MA) in chronic kidney disease using sodium bicarbonate (NaHCO3)
Figure 4: Total Prevalence of CKD patients in the 7MM+3EM (2017-2030)
Figure 5: Total Prevalence of Metabolic Acidosis in CKD patients of the 7MM+3EM (2017-2030)
Figure 6: Total Prevalence of dRTA in the 7MM+3EM (2017-2030)
Figure 7: Total Diagnosed Population of Metabolic Acidosis in the 7MM+3EM (2017-2030)
Figure 8: Total Diagnosed Population of dRTA in the 7MM+3EM (2017-2030)
Figure 9: Gender-Specific diagnosed cases of Metabolic Acidosis in the 7MM+3EM (2017-2030)
Figure 10: Total Treated Population of Metabolic Acidosis in the 7MM+3EM (2017-2030)
Figure 11: Total Treated Population of dRTA in the 7MM+3EM (2017-2030)
Figure 12: Total Prevalent Population of Metabolic Acidosis in the United States (2017-2030)
Figure 13: Total Prevalent Population of dRTA in the United States (2017-2030)
Figure 14: Total Diagnosed Population of Metabolic Acidosis in the United States (2017-2030)
Figure 15: Total Diagnosed Population of dRTA in the United States (2017-2030)
Figure 16: Total Treated Population of Metabolic Acidosis in the United States (2017-2030)
Figure 17: Total Treated Population of dRTA in the United States (2017-2030)
Figure 18: Total Prevalent Population of Metabolic Acidosis in Germany (2017-2030)
Figure 19: Total Prevalent Population of dRTA in Germany (2017-2030)
Figure 20: Total Diagnosed Population of Metabolic Acidosis in Germany (2017-2030)
Figure 21: Total Diagnosed Population of dRTA in Germany (2017-2030)
Figure 22: Total Treated Population of Metabolic Acidosis in Germany (2017-2030)
Figure 23: Total Treated Population of dRTA in Germany (2017-2030)
Figure 24: Total Prevalent Population of Metabolic Acidosis in France (2017-2030)
Figure 25: Total Prevalent Population of dRTA in France (2017-2030)
Figure 26: Total Diagnosed Population of Metabolic Acidosis in France (2017-2030)
Figure 27: Total Diagnosed Population of dRTA in France (2017-2030)
Figure 28: Total Treated Population of Metabolic Acidosis in France (2017-2030)
Figure 29: Total Treated Population of dRTA in France (2017-2030)
Figure 30: Total Prevalent Population of Metabolic Acidosis in Italy (2017-2030)
Figure 31: Total Prevalent Population of dRTA in Italy (2017-2030)
Figure 32: Total Diagnosed Population of Metabolic Acidosis in Italy (2017-2030)
Figure 33: Total Diagnosed Population of dRTA in Italy (2017-2030)
Figure 34: Total Treated Population of Metabolic Acidosis in Italy (2017-2030)
Figure 35: Total Treated Population of dRTA in Italy (2017-2030)
Figure 36: Total Prevalent Population of Metabolic Acidosis in Spain (2017-2030)
Figure 37: Total Prevalent Population of dRTA in Spain (2017-2030)
Figure 38: Total Diagnosed Population of Metabolic Acidosis in Spain (2017-2030)
Figure 39: Total Diagnosed Population of dRTA in Spain (2017-2030)
Figure 40: Total Treated Population of Metabolic Acidosis in Spain (2017-2030)
Figure 41: Total Treated Population of dRTA in Spain (2017-2030)
Figure 42: Total Prevalent Population of Metabolic Acidosis in the United Kingdom (2017-2030)
Figure 43: Total Prevalent Population of dRTA in the United Kingdom (2017-2030)
Figure 44: Total Diagnosed Population of Metabolic Acidosis in the United Kingdom (2017-2030)
Figure 45: Total Diagnosed Population of dRTA in the United Kingdom (2017-2030)
Figure 46: Total Treated Population of Metabolic Acidosis in the United Kingdom (2017-2030)
Figure 47: Total Treated Population of dRTA in the United Kingdom (2017-2030)
Figure 48: Total Prevalent Population of Metabolic Acidosis in Japan (2017-2030)
Figure 49: Total Prevalent Population of dRTA in Japan (2017-2030)
Figure 50: Total Diagnosed Population of Metabolic Acidosis in Japan (2017-2030)
Figure 51: Total Diagnosed Population of dRTA in Japan (2017-2030)
Figure 52: Total Treated Population of Metabolic Acidosis in Japan (2017-2030)
Figure 53: Total Treated Population of dRTA in Japan (2017-2030)
Figure 54: Total Prevalent Population of Metabolic Acidosis in Brazil (2017-2030)
Figure 55: Total Prevalent Population of dRTA in Brazil (2017-2030)
Figure 56: Total Diagnosed Population of Metabolic Acidosis in Brazil (2017-2030)
Figure 57: Total Diagnosed Population of dRTA in Brazil (2017-2030)
Figure 58: Total Treated Population of Metabolic Acidosis in Brazil (2017-2030)
Figure 59: Total Treated Population of dRTA in Brazil (2017-2030)
Figure 60: Total Prevalent Population of Metabolic Acidosis in China (2017-2030)
Figure 61: Total Prevalent Population of dRTA in China (2017-2030)
Figure 62: Total Diagnosed Population of Metabolic Acidosis in China (2017-2030)
Figure 63: Total Diagnosed Population of dRTA in China (2017-2030)
Figure 64: Total Treated Population of Metabolic Acidosis in China (2017-2030)
Figure 65: Total Treated Population of dRTA in China (2017-2030)
Figure 66: Total Prevalent Population of Metabolic Acidosis in Mexico (2017-2030)
Figure 67: Total Prevalent Population of dRTA in Mexico (2017-2030)
Figure 68: Total Diagnosed Population of Metabolic Acidosis in Mexico (2017-2030)
Figure 69: Total Diagnosed Population of dRTA in Mexico (2017-2030)
Figure 70: Total Treated Population of Metabolic Acidosis in Mexico (2017-2030)
Figure 71: Total Treated Population of dRTA in Mexico (2017-2030)
Figure 72: Adverse effects of acute metabolic acidosis
Figure 73: Adverse effects of chronic metabolic acidosis
Figure 74: Increased mean serum bicarbonate (SBC) throughout the 2-week treatment period
Figure 75: Increased mean serum bicarbonate (SBC) changes on Day 15
Figure 76: Market size of metabolic acidosis in the 7MM+3EM, USD Million (2017-2030)
Figure 77: Market size of metabolic acidosis by therapies in the 7MM+3EM, USD Million (2017-2030)
Figure 78: Market size of metabolic acidosis in the United States, USD Million (2017-2030)
Figure 79: Market size of metabolic acidosis by therapies in the United States, USD Million (2017-2030)
Figure 80: Market size of metabolic acidosis in Germany, USD Million (2017-2030)
Figure 81: Market size of metabolic acidosis by therapies in Germany, USD Million (2017-2030)
Figure 82: Market size of metabolic acidosis in France, USD Million (2017-2030)
Figure 83: Market size of metabolic acidosis by therapies in France, USD Million (2017-2030)
Figure 84: Market size of metabolic acidosis in Italy, USD Million (2017-2030)
Figure 85: Market size of metabolic acidosis by therapies in Italy, USD Million (2017-2030)
Figure 86: Market size of metabolic acidosis in Spain, USD Million (2017-2030)
Figure 87: Market size of metabolic acidosis by therapies in Spain, USD Million (2017-2030)
Figure 88: Market size of metabolic acidosis in the United Kingdom, USD Million (2017-2030)
Figure 89: Market size of metabolic acidosis by therapies in the United Kingdom, USD Million (2017-2030)
Figure 90: Market size of metabolic acidosis in Japan, USD Million (2017-2030)
Figure 91: Market size of metabolic acidosis by therapies in Japan, USD Million (2017-2030)
Figure 92: Market size of metabolic acidosis in Brazil, USD Million (2017-2030)
Figure 93: Market size of metabolic acidosis by therapies in Brazil, USD Million (2017-2030)
Figure 94: Market size of metabolic acidosis in China, USD Million (2017-2030)
Figure 95: Market size of metabolic acidosis by therapies in China, USD Million (2017-2030)
Figure 96: Market size of metabolic acidosis in Mexico, USD Million (2017-2030)
Figure 97: Market size of metabolic acidosis by therapies in Mexico, USD Million (2017-2030)

 

List of Tables


Table 1: Summary of Metabolic Acidosis Market, Epidemiology, and Key Events (2017?2030)
Table 2: Total Prevalence of CKD patients in the 7MM+3EM (2017?2030)
Table 3: Total Prevalence of Metabolic Acidosis in CKD patients of the 7MM+3EM (2017?2030)
Table 4: Total Prevalence of dRTA in the 7MM+3EM (2017?2030)
Table 5: Total Diagnosed Population of Metabolic Acidosis in the 7MM+3EM (2017–2030)
Table 6: Total Diagnosed Population of dRTA in the 7MM+3EM (2017–2030)
Table 7: Gender-Specific diagnosed cases of Metabolic Acidosis in the 7MM+3EM (2017–2030)
Table 8: Total Treated Population of Metabolic Acidosis in the 7MM+3EM (2017–2030)
Table 9: Total Treated Population of dRTA in the 7MM+3EM (2017–2030)
Table 10: Total Prevalent Population of Metabolic Acidosis in the United States (2017–2030)
Table 11: Total Prevalent Population of dRTA in the United States (2017–2030)
Table 12: Total Diagnosed Population of Metabolic Acidosis in the United States (2017–2030)
Table 13: Total Diagnosed Population of Metabolic Acidosis in the United States (2017–2030)
Table 14: Total Treated Population of Metabolic Acidosis in the United States (2017–2030)
Table 15: Total Treated Population of dRTA in the United States (2017–2030)
Table 16: Total Prevalent Population of Metabolic Acidosis in Germany (2017–2030)
Table 17: Total Prevalent Population of dRTA in Germany (2017–2030)
Table 18: Total Diagnosed Population of Metabolic Acidosis in Germany (2017–2030)
Table 19: Total Diagnosed Population of dRTA in Germany (2017–2030)
Table 20: Total Treated Population of Metabolic Acidosis in Germany (2017–2030)
Table 21: Total Treated Population of dRTA in Germany (2017–2030)
Table 22: Total Prevalent Population of Metabolic Acidosis in France (2017–2030)
Table 23: Total Prevalent Population of dRTA in France (2017–2030)
Table 24: Total Diagnosed Population of Metabolic Acidosis in France (2017–2030)
Table 25: Total Diagnosed Population of dRTA in France (2017–2030)
Table 26: Total Treated Population of Metabolic Acidosis in France (2017–2030)
Table 27: Total Treated Population of dRTA in France (2017–2030)
Table 28: Total Prevalent Population of Metabolic Acidosis in Italy (2017–2030)
Table 29: Total Prevalent Population of dRTA in Italy (2017–2030)
Table 30: Total Diagnosed Population of Metabolic Acidosis in Italy (2017–2030)
Table 31: Total Diagnosed Population of dRTA in Italy (2017–2030)
Table 32: Total Treated Population of Metabolic Acidosis in Italy (2017–2030)
Table 33: Total Treated Population of dRTA in Italy (2017–2030)
Table 34: Total Prevalent Population of Metabolic Acidosis in Spain (2017–2030)
Table 35: Total Prevalent Population of dRTA in Spain (2017–2030)
Table 36: Total Diagnosed Population of Metabolic Acidosis in Spain (2017–2030)
Table 37: Total Diagnosed Population of dRTA in Spain (2017–2030)
Table 38: Total Treated Population of Metabolic Acidosis in Spain (2017–2030)
Table 39: Total Treated Population of dRTA in Spain (2017–2030)
Table 40: Total Prevalent Population of Metabolic Acidosis in the United Kingdom (2017–2030)
Table 41: Total Prevalent Population of dRTA in the United Kingdom (2017–2030)
Table 42: Total Diagnosed Population of Metabolic Acidosis in the United Kingdom (2017–2030)
Table 43: Total Diagnosed Population of dRTA in the United Kingdom (2017–2030)
Table 44: Total Treated Population of Metabolic Acidosis in the United Kingdom (2017–2030)
Table 45: Total Treated Population of dRTA in the United Kingdom (2017–2030)
Table 46: Total Prevalent Population of Metabolic Acidosis in Japan (2017–2030)
Table 47: Total Prevalent Population of dRTA in Japan (2017–2030)
Table 48: Total Diagnosed Population of Metabolic Acidosis in Japan (2017–2030)
Table 49: Total Diagnosed Population of dRTA in Japan (2017–2030)
Table 50: Total Treated Population of Metabolic Acidosis in Japan (2017–2030)
Table 51: Total Treated Population of dRTA in Japan (2017–2030)
Table 52: Total Prevalent Population of Metabolic Acidosis in Brazil (2017–2030)
Table 53: Total Prevalent Population of dRTA in Brazil (2017–2030)
Table 54: Total Diagnosed Population of Metabolic Acidosis in Brazil (2017–2030)
Table 55: Total Diagnosed Population of dRTA in Brazil (2017–2030)
Table 56: Total Treated Population of Metabolic Acidosis in Brazil (2017–2030)
Table 57: Total Treated Population of dRTA in Brazil (2017–2030)
Table 58: Total Prevalent Population of Metabolic Acidosis in China (2017–2030)
Table 59: Total Prevalent Population of dRTA in China (2017–2030)
Table 60: Total Diagnosed Population of Metabolic Acidosis in China (2017–2030)
Table 61: Total Diagnosed Population of dRTA in China (2017–2030)
Table 62: Total Treated Population of Metabolic Acidosis in China (2017–2030)
Table 63: Total Treated Population of dRTA in China (2017–2030)
Table 64: Total Prevalent Population of Metabolic Acidosis in Mexico (2017–2030)
Table 65: Total Prevalent Population of dRTA in Mexico (2017–2030)
Table 66: Total Diagnosed Population of Metabolic Acidosis in Mexico (2017–2030)
Table 67: Total Diagnosed Population of dRTA in Mexico (2017–2030)
Table 68: Total Treated Population of Metabolic Acidosis in Mexico (2017–2030)
Table 69: Total Treated Population of dRTA in Mexico (2017–2030)
Table 70: Commonly Prescribed Alkalinizing Agents, Dosages, and Considerations
Table 71: Recommendation according to the GRADE methodology
Table 72: Summary of recommendations
Table 73: TRC101, Clinical Trial Description
Table 74: ADV7103, Clinical Trial Description
Table 75: Market size of metabolic acidosis in the 7MM+3EM, USD Million (2017-2030)
Table 76: Market size of metabolic acidosis by therapies in the 7MM+3EM, USD Million (2017-2030)
Table 77: Market size of metabolic acidosis in the United States, USD Million (2017-2030)
Table 78: Market size of metabolic acidosis by therapies in the United States, USD Million (2017-2030)
Table 79: Market size of metabolic acidosis in Germany, USD Million (2017-2030)
Table 80: Market size of metabolic acidosis by therapies in Germany, USD Million (2017-2030)
Table 81: Market size of metabolic acidosis in France, USD Million (2017-2030)
Table 82: Market size of metabolic acidosis by therapies in France, USD Million (2017-2030)
Table 83: Market size of metabolic acidosis in Italy, USD Million (2017-2030)
Table 84: Market size of metabolic acidosis by therapies in Italy, USD Million (2017-2030)
Table 85: Market size of metabolic acidosis in Spain, USD Million (2017-2030)
Table 86: Market size of metabolic acidosis by therapies in Spain, USD Million (2017-2030)
Table 87: Market size of metabolic acidosis in the United Kingdom, USD Million (2017-2030)
Table 88: Market size of metabolic acidosis by therapies in the United Kingdom, USD Million (2017-2030)
Table 89: Market size of metabolic acidosis in Japan, USD Million (2017-2030)
Table 90: Market size of metabolic acidosis by therapies in Japan, USD Million (2017-2030)
Table 91: Market size of metabolic acidosis in Brazil, USD Million (2017-2030)
Table 92: Market size of metabolic acidosis by therapies in Brazil, USD Million (2017-2030)
Table 93: Market size of metabolic acidosis in China, USD Million (2017-2030)
Table 94: Market size of metabolic acidosis by therapies in China, USD Million (2017-2030)
Table 95: Market size of metabolic acidosis in Mexico, USD Million (2017-2030)
Table 96: Market size of metabolic acidosis by therapies in Mexico, USD Million (2017-2030)